27 Sep 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Global autoimmune disease diagnostics market is estimated to reach $1 billion in 2018 from $712.5 million in 2012, according to a new analysis by Frost & Sullivan.
Successful autoimmune disease awareness campaigns are encouraging patients to seek clinical diagnostics even for general symptoms such as fatigue and gastrointestinal distress, spurring the global autoimmune disease diagnostics market. The rising incidence of gastrointestinal autoimmune conditions, primarily celiac disease, also promotes testing.
The US market will be the highest contributor to the growth of the global autoimmune disease diagnostics market, especially as the Patient Protection and Affordable Care Act expands health coverage to at least 19.5 million people in the country. The increase in the number of beneficiaries will lead to higher diagnostic testing of patients with autoimmune disease symptoms.
"Large advertising campaigns for relatively new autoimmune disease medications treating a wide variety of autoimmune diseases, including rheumatoid arthritis, chronic plaque psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, and polyarticular juvenile idiopathic arthritis improved patient awareness," said a Frost & Sullivan Healthcare research analyst. "The subsequent growth in testing volumes will prompt clinical laboratories to employ advanced autoimmune disease diagnostic tests."
However, due to the broad range of symptoms associated with autoimmune diseases, clinicians regularly struggle to derive the correct diagnosis, compelling some physicians to question the value of autoimmune disease diagnostics. In fact, as much as 30 percent of healthy patients test positive incorrectly and undergo unnecessary therapies and procedures.
Moreover, several autoimmune disease diagnostic tests are designed for manual operation, and the shortage of skilled technicians limits uptake. Handling certain therapies such as enzyme-linked immunosorbent assay kits and indirect immunofluorescent assays (IFA) that are often designated as highly complex becomes all the more difficult. This created immense demand for automated diagnostic platforms that facilitate rapid and efficient testing.
"Test panels that enable the simultaneous use of multiple autoimmune disease diagnostics will provide the greatest value," said the analyst. "Although the price per test may decline, escalating sale volumes will fuel market growth."